# Induction Chemotherapy Combined With Toripalimab in Locoregionally-Advanced Laryngo-Hypopharyngeal Squamous Cell Cancer

> **NCT04926753** · PHASE1 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Locoregionally Advanced Laryngo-hypopharyngeal Squamous Cell Cancer

## Interventions

- **DRUG:** 5-Fluorouracil, Cisplatin, Toripalimab

## Key facts

- **NCT ID:** NCT04926753
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-01
- **Primary completion:** 2022-12-01
- **Final completion:** 2024-06-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04926753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04926753, "Induction Chemotherapy Combined With Toripalimab in Locoregionally-Advanced Laryngo-Hypopharyngeal Squamous Cell Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04926753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*